Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
; : 174-179, 2023.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-1003023
Responsible library:
WPRO
ABSTRACT
The escalating prevalence of clarithromycin resistance in cases of Helicobacter pylori, insufficient acid suppression, and pharmacodynamic variations secondary to inter-individual differences in CYP2C19 polymorphism collectively contribute to suboptimal eradication rates observed with proton pump inhibitor (PPI)-based therapy. Compared with PPIs, potassium-competitive acid blockers (PCABs) produce rapid, potent, and long-lasting suppression of gastric acid through reversible inhibition of gastric H+, K+-ATPase. PCAB-based therapy results in significant inhibition of acid secretion and has therefore emerged as a novel and effective approach for H. pylori eradication. In this study, we review the efficacy and safety profile of PCAB-based eradication regimens comprising vonoprazan, tegoprazan, and fexuprazan.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Korean
Journal:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Year:
2023
Document type:
Article